Published in Women's Health Weekly, September 30th, 2004
The study, being conducted at two study centers in Singapore, began enrollment in June 2004.
The double-blind study compares Dynavax's HBV vaccine candidate with GlaxoSmithKline's marketed HBV vaccine, Engerix-B, in 94 subjects. The subjects, ranging between 40-70 years of age, had not previously been immunized against HBV. The full immunization schedule will consist of three injections over 6 months, with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly